Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

Published:2018-01-08 Issue:5 Volume:47 Page:588-595
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Wils P.¹,Bouhnik Y.²,Michetti P.³^ORCID,Flourie B.⁴,Brixi H.⁵,Bourrier A.⁶,Allez M.⁶,Duclos B.⁷,Serrero M.⁸,Buisson A.⁹^ORCID,Amiot A.¹⁰^ORCID,Fumery M.¹¹,Roblin X.¹²^ORCID,Peyrin-Biroulet L.¹³^ORCID,Filippi J.¹⁴,Bouguen G.¹⁵^ORCID,Abitbol V.⁶,Coffin B.¹⁶,Simon M.⁶,Laharie D.¹⁷^ORCID,Pariente B.¹^ORCID,

Affiliation:

1. Lille France

2. Clichy France

3. Lausanne Switzerland

4. Lyon France

5. Reims France

6. Paris France

7. Strasbourg France

8. Marseille France

9. Clermont-Ferrand France

10. Créteil France

11. Amiens France

12. Saint Etienne France

13. Nancy France

14. Nice France

15. Rennes France

16. Colombes France

17. Bordeaux France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14487/fullpdf

Reference22 articles.

1. Development of the Crohn's disease digestive damage score, the Lémann score;Pariente;Inflamm Bowel Dis,2011

2. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease;Pariente;Gastroenterology,2015

3. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health;Peyrin-Biroulet;Inflamm Bowel Dis,2010

4. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience;Billiet;Aliment Pharmacol Ther,2016

5. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vedolizumab versus ustekinumab in Crohn’s disease with prior anti-tumor necrosis factor failure: an updated meta-analysis;European Journal of Gastroenterology & Hepatology;2024-07-02

2. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years;Scientific Reports;2024-06-28

3. Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease;The Korean Journal of Gastroenterology;2024-06-25

4. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data;Digestive and Liver Disease;2024-05

5. Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease;Alimentary Pharmacology & Therapeutics;2024-04-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3